An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII
Elisabeth Husar(Roche (Switzerland)), Antje‐Christine Walz(Roche (Switzerland)), Afsaneh Abdolzade‐Bavil(Roche Pharma AG (Germany)), Miro J. Eigenmann(Roche (Switzerland)), Roberto Villaseñor(Roche (Switzerland)), Reto Gianotti(Roche (Switzerland)), Nikolche Gjorevski(Roche (Switzerland)), Alina Gavrilov(Max Planck Institute of Immunobiology and Epigenetics), Anne Freimoser–Grundschober(Roche (Switzerland)), Inja Waldhauer(Roche (Switzerland)), Nadine Stokar‐Regenscheit(Roche (Switzerland)), Patrício Godoy(Roche (Switzerland)), Valeria Nicolini(Roche (Switzerland)), Andreas Hollenstein(Roche (Switzerland)), Angélique Augustin(Roche (Switzerland)), Liudmila Polonchuk(Roche (Switzerland)), Martin Lechmann(Roche (Switzerland))
Cited by 0
Related Papers
The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells
|Nature Neuroscience|2021|264
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection
|Proceedings of the National Academy of Sciences|2003|170
Immunopurification and Mass Spectrometric Quantification of the Active Form of a Chimeric Therapeutic Antibody in Human Serum
|Analytical Chemistry|2008|144
Vaccination trial with HPV16 L1E7 chimeric virus‐like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3)
|International Journal of Cancer|2007|136